Cancer therapy-related cardiac dysfunction (CTRCD) contributes to incident heart failure (HF) in cancer survivors, yet population-based estimates of its incidence have been limited. The Kaiser Permanente Cardiovascular Health Enhancement and Monitoring for Oncology (KP CHEMO) study provides real-world data on CTRCD incidence, timing, and treatment-specific variation, offering a clearer understanding of this complication.1

Contemporary oncologic treatments, while effective against cancer, carry a known risk of cardiac complications, particularly cancer therapy-related cardiac dysfunction (CTRCD). This dysfunction is a significant contributor to the development of heart failure (HF) among cancer survivors.1,2 Despite the recognition of certain cardiotoxic cancer therapies, comprehensive population-based estimates of CTRCD incidence in large, diverse, and contemporary patient cohorts have been scarce.1,2

The KP CHEMO Study and Multimodality Imaging Consensus

The Kaiser Permanente Cardiovascular Health Enhancement and Monitoring for Oncology (KP CHEMO) study aimed to address this data gap by determining the incidence, timing, and treatment-specific variation of CTRCD within an integrated US health system.1 This study provides essential real-world data on how frequently CTRCD occurs and when it typically manifests in relation to different cancer treatments. The findings from KP CHEMO contribute to a more precise understanding of the burden of CTRCD, moving beyond theoretical risks to observed outcomes in a broad patient population.1

Complementing these incidence data, a clinical consensus statement from the ESC Council of Cardio-Oncology and the European Association of Cardiovascular Imaging (EACVI) of the ESC addresses the role of multimodality imaging in detecting and managing cardiovascular complications.2 This statement specifically focuses on coronary and peripheral arterial disease in patients receiving cardiotoxic antineoplastic treatments.2 The consensus highlights the importance of various imaging techniques to identify and monitor cardiovascular issues that may arise from cancer therapies. This includes, but is not limited to, the detection of CTRCD, which is a primary concern in cardio-oncology.2 The statement underscores that a comprehensive imaging approach is necessary for effective management, allowing for early detection and intervention to mitigate the long-term cardiac sequelae of cancer treatment.2

Both the KP CHEMO study and the ESC/EACVI consensus statement reinforce the necessity of vigilant cardiovascular monitoring in patients undergoing cancer therapy. The KP CHEMO data provides the epidemiological context, detailing the real-world occurrence of CTRCD.1 The consensus statement, in turn, offers practical guidance on how to implement effective surveillance using advanced imaging modalities.2 Together, these publications provide a more complete picture for clinicians, from understanding the prevalence of CTRCD to establishing best practices for its detection and management in patients with cancer and cancer survivors.1,2

Clinical Implications

The KP CHEMO study's quantification of CTRCD incidence by specific cancer therapy is a welcome dose of reality. For too long, discussions around cardiotoxicity have been broad, often lumping disparate agents together. This new data allows clinicians to move beyond general awareness to a more nuanced risk assessment, particularly when selecting or monitoring patients on known cardiotoxic agents. It should prompt a re-evaluation of current monitoring protocols, ensuring that surveillance is tailored to the specific treatment regimen rather than a one-size-fits-all approach. The days of simply 'being aware' of cardiotoxicity are over; now, we have a clearer picture of when and with what agents to be most vigilant.

The ESC/EACVI consensus on multimodality imaging further solidifies the need for proactive cardiovascular assessment. It is no longer sufficient to wait for symptomatic heart failure. Early detection of subclinical changes via advanced imaging, as outlined in the consensus, is paramount. This places a greater onus on cardiologists and oncologists to collaborate, integrating imaging protocols into the patient's cancer treatment pathway. Investment in appropriate imaging infrastructure and training for specialists will be critical. Without it, the insights from KP CHEMO on incidence will remain academic, failing to translate into improved patient outcomes.

From an industry perspective, these findings highlight the ongoing need for novel cancer therapies with improved cardiovascular safety profiles. The data from KP CHEMO provides a baseline against which new agents can be compared. Furthermore, the emphasis on multimodality imaging may drive innovation in diagnostic technologies, particularly those offering non-invasive, high-resolution assessment of cardiac function. Pharmaceutical companies developing cardiotoxic agents should consider robust cardio-oncology programmes as standard, not an afterthought, ensuring that the benefits of cancer treatment are not undermined by preventable cardiac morbidity.

Key Takeaways
  • The Pivot Real-world data now quantifies CTRCD incidence and its variation across specific cancer therapies in a large, diverse cohort.
  • The Data The KP CHEMO study determined the incidence, timing, and treatment-specific variation in CTRCD.1
  • The Action Clinicians should consider specific cardiotoxic cancer therapies when monitoring for CTRCD, utilising multimodality imaging as per consensus statements.

ART-2026-322

06/26

Save as PDF
Reviewed & published by
Editorial Team
Cite This Article

Team TLSFE. Ctrcd incidence varies by cancer therapy in kp chemo study. The Life Science Feed. Published June 20, 2026. Updated June 20, 2026. Accessed June 20, 2026. https://thelifesciencefeed.com/cardiology/cardiomyopathies/news/ctrcd-incidence-varies-by-cancer-therapy-in-kp-chemo-study.

Editorial & AI Standards

All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.

Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.

Licence & Rights

© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.

Medical Disclaimer

The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

References

1. Thadani SR, Go AS, Liu JY. Real-world incidence of cancer therapy-related cardiac dysfunction in a large, diverse, and contemporary cohort. ESC Heart Fail 2026. PMID: 42063389.

2. Novo G, Lopez-Fernandez T, Delgado V. Multimodality imaging in the detection and management of coronary and peripheral arterial disease in patients with cancer receiving cardiotoxic antineoplastic treatments. A clinical consensus statement of the ESC Council of Cardio-Oncology and the European Association of Cardiovascular Imaging (EACVI) of the ESC. Eur Heart J Cardiovasc Imaging 2026. PMID: 42025328.